文献速递分子诊断临床微生物质量管理与危急值

三种SARS-CoV-2核酸检测试剂的分析与临床性能比较

Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection.
PubMed 文献 · J Clin Microbiol · 2020-08-24

本研究比较了Hologic Panther Fusion、Hologic Aptima和BioFire Defense三种SARS-CoV-2核酸扩增检测的分析性能、临床性能和工作流程。三种方法使用灭活病毒的检测限相似(500–1,000 genome equivalents/ml),但使用RNA转录标准品时绝对检测限存在差异(62.5–125 copies/ml)。与共识结果相比,Fusion和BioFire的阳性符合率为98.7%,Aptima为94.7%;三者阴性符合率均为100%。

要点

  • 三种试剂相对检测限相似,但绝对检测限因参考标准不同而异。
  • Fusion和BioFire临床阳性符合率优于Aptima,阴性符合率均达100%。
  • Aptima漏检样本在Fusion中Ct值均>37,提示低病毒载量影响检出。

核心结论

  • 三种试剂相对检测限相似,但绝对检测限因所用标准品不同而存在差异,Fusion和BioFire临床性能更优。

研究设计与样本

  • 对比三种FDA EUA授权的SARS-CoV-2核酸扩增检测(Fusion、Aptima、BioFire)的分析性能、临床性能与工作流程。

主要发现

  • 使用灭活病毒时三种试剂检测限均为500–1,000 genome equivalents/ml且100%检出。
  • 使用RNA转录标准品时检测限范围为62.5–125 copies/ml,趋势相同但绝对值不同。
  • Fusion和BioFire阳性符合率98.7%,Aptima为94.7%;三者阴性符合率均为100%。
  • Aptima漏检的4例样本在Fusion中Ct值均>37。

关键数值与推荐

  • 阳性符合率:Fusion 98.7%,BioFire 98.7%,Aptima 94.7%(与共识结果比较)。
  • 阴性符合率:三种试剂均为100%。
  • 检测限(灭活病毒):500–1,000 genome equivalents/ml,100%检出。
  • 检测限(RNA转录标准品):62.5–125 copies/ml。

临床怎么用

  • 选择平台时应考虑试剂绝对检测限受标准品影响及临床符合率差异。
  • 对低病毒载量样本(如Fusion Ct>37)需关注Aptima可能漏检的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 and has quickly become a worldwide pandemic. In response, many diagnostic manufacturers have developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) pathway. This study compared three of these assays, the Hologic Panther Fusion SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima), and the BioFire Defense COVID-19 test (BioFire), to determine analytical and clinical performance as well as workflow. All three assays showed similar limits of detection (LODs) using inactivated virus, with 100% detection, ranging from 500 to 1,000 genome equivalents/ml, whereas use of a quantified RNA transcript standard showed the same trend but had values ranging from 62.5 to 125 copies/ml, confirming variability in absolute quantification of reference standards. The clinical correlation found that the Fusion and BioFire assays had a positive percent agreement (PPA) of 98.7%, followed by the Aptima assay at 94.7%, compared to the consensus result. All three assays exhibited 100% negative percent agreement (NPA). Analysis of discordant results revealed that all four samples missed by the Aptima assay had cycle threshold (Ct ) values of >37 by the Fusion assay. In conclusion, while all three assays showed similar relative LODs, we showed differences in absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. These findings should be kept in mind when making platform testing decisions.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Smith E, Zhen W, Manji R, et al. Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection. J Clin Microbiol. 2020. PMID: 32571894. doi:10.1128/JCM.01134-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。